Head to Head Review: Vivani Medical (NASDAQ:VANI) vs. Getinge AB (publ) (OTCMKTS:GNGBY)

Getinge AB (publ) (OTCMKTS:GNGBY) and Vivani Medical (NASDAQ:VANI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

6.8% of Vivani Medical shares are owned by institutional investors. 44.3% of Vivani Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Getinge AB (publ) and Vivani Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Getinge AB (publ)	$3.00 billion	1.49	$227.45 million	$0.59	27.87
Vivani Medical	N/A	N/A	-$25.65 million	($0.45)	-2.62

Getinge AB (publ) has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Getinge AB (publ), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Getinge AB (publ) and Vivani Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Getinge AB (publ)	5.04%	8.27%	4.60%
Vivani Medical	N/A	-102.42%	-49.21%

Analyst Recommendations

This is a breakdown of recent ratings for Getinge AB (publ) and Vivani Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Getinge AB (publ)	0	0	0	0	0.00
Vivani Medical	0	0	1	0	3.00

Vivani Medical has a consensus price target of $3.00, indicating a potential upside of 154.24%. Given Vivani Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Vivani Medical is more favorable than Getinge AB (publ).

Risk and Volatility

Getinge AB (publ) has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Vivani Medical has a beta of 3.16, meaning that its stock price is 216% more volatile than the S&P 500.

Summary

Getinge AB (publ) beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

About Getinge AB (publ)

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.